GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that senior management will present corporate updates at two upcoming investor conferences in April. Details are as follows:
HC WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE
Who: Chief Financial Officer Brian Hahn
When: Tuesday, April 9 at 2:10 p.m. (GMT)
Where: London, UK
18TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Who: Chief Executive Officer Rachel King
When: Wednesday, April 10 at 3:30 p.m. (ET)
Where: New York, NY
To access the live webcast and subsequent archived recordings for each of these presentations, please visit the GlycoMimetics website at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.